razoxane has been researched along with Adenocarcinoma Of Kidney in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anderson, H; Harris, AL; Miller, MP; Price, P; Propper, D; Wells, P; Yap, JT | 1 |
| Blann, A; Braybrooke, JP; Crew, J; Dobbs, N; Ganesan, TS; Han, C; Harris, AL; Mitchell, K; O'Byrne, KJ; Propper, DJ; Saunders, M; Smith, K; Stephens, R; Talbot, DC; Woodhull, J | 1 |
2 trial(s) available for razoxane and Adenocarcinoma Of Kidney
| Article | Year |
|---|---|
Measurement of renal tumour and normal tissue perfusion using positron emission tomography in a phase II clinical trial of razoxane.
Topics: Antineoplastic Agents; Carbon Monoxide; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Neovascularization, Pathologic; Oxygen Radioisotopes; Razoxane; Regional Blood Flow; Tomography, Emission-Computed; Water | 2003 |
A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Carcinoma, Renal Cell; Disease-Free Survival; E-Selectin; Endothelial Growth Factors; Female; Fibroblast Growth Factor 2; Humans; Kidney Neoplasms; Lymphokines; Male; Middle Aged; Neovascularization, Pathologic; Razoxane; Receptors, Cell Surface; Receptors, Urokinase Plasminogen Activator; Time Factors; Topoisomerase II Inhibitors; Treatment Outcome; Vascular Cell Adhesion Molecule-1; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; von Willebrand Factor | 2000 |